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72-year-old woman is admitted with fever and shortness of breath. Chest radiography demonstrates a consolidation in the right lower lobe, and ceftriaxone and azithromycin are given to treat community-acquired pneumonia. After initial improvement she develops abdominal discomfort and profuse diarrhea on day 5 of hospitalization. What stool testing should be ordered?
Most cases of diarrhea in hospitalized patients are not due to infection, but the most common infectious cause is Clostridium difficile. In the absence of unusual circumstances such as a norovirus outbreak or diarrhea in an immunocompromised patient, testing for C diffi cile is the only recommended assay. A multistep algorithm with a combination of antigen detection and nucleic acid amplifi cation techniques provides the best sensitivity and specifi city. Repeated testing after an initially negative test and performing a test of cure are of limited utility and incur added costs, and thus are not recommended.
■ CAUSES OF DIARRHEA IN THE HOSPITAL
Diarrhea is defi ned as at least 1 day with three or more unformed stools or a signifi cant increase in stool frequency above baseline.
Nosocomial diarrhea is an acute episode of diarrhea in a hospitalized patient that was not present on admission and that arises after 3 days of hospitalization. It is fairly common, developing in 12% to 32% of patients at some point during their hospitalization. 1 Most cases of nosocomial diarrhea are not due to infection, but rather secondary to enteral feeding, medications, and underlying illness. C diffi cile is the most common infectious cause and accounts for 10% to 20% of all cases of nosocomial diarrhea. 2 Other pathogens associated with nosocomial diarrhea are unusual, although outbreaks of norovirus in healthcare facilities have occurred, 3 and isolated cases of Klebsiella oxytoca causing acute abdominal pain, bloody diarrhea, and leukocytosis after exposure to antibiotics have been reported. 1 
■ RECOMMENDED TESTING
The evaluation of a hospitalized patient in whom diarrhea develops should initially focus on the clinical presentation, with attention to signs of sepsis. Stable patients with mild symptoms may respond to withdrawal of the offending agent (if any), while patients with moderate or severe symptoms (including those with fever, hypotension, leukocytosis, acute kidney injury, or a decreased serum bicarbonate level) should be tested for C diffi cile infection (Figure 1) .
In general, stool testing should adhere to the "3-day rule"-ie, fecal specimens from patients with diarrhea that develops after 3 days of hospitalization have a very low yield when cultured for standard bacteria or examined for ova and parasites. Thus, only testing for C diffi cile infection should be ordered.
In an outbreak of norovirus, especially if vomiting is present, norovirus testing by reverse transcriptase polymerase chain reaction (PCR) could be considered.
Fecal white blood cell testing should not be ordered, as it neither sensitive nor specifi c. What stool testing is appropriate when diarrhea develops in a hospitalized patient?
RAMDEEN AND WORTMANN
Immunocompromised patients (such as those with organ transplants or late-stage human immunodefi ciency virus infection) occasionally contract diarrhea due to causes other than C diffi cile, and consultation with a gastroenterologist or an infectious diseases physician could be considered if diarrhea persists and no cause is apparent.
In the rare situation when a patient is hospitalized after very recent overseas travel and then contracts diarrhea, causes of traveler's diarrhea should be considered.
■ TESTING FOR C DIFFICILE INFECTION
A number of diagnostic tests for C diffi cile infection are available.
Toxigenic culture (culture followed by detection of a toxigenic isolate) and C diffi cile cytotoxin neutralization assay are considered the reference standards, having high sensitivity and specifi city. However, both are timeand labor-intensive, with turnaround times of at least 2 to 3 days and up to 9 days, limiting their clinical utility and resulting in delay in both diagnosis and implementation of infection control measures.
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Enzyme immunoassays (EIAs) are faster. EIAs are available to detect glutamate dehydrogenase (GDH) and toxins A and B, all produced by C diffi cile. The GDH EIA is 92% sensitive and 93% specifi c but should not be used alone as it does not distinguish between toxigenic and nontoxigenic strains of C difficile. 2, 6 The toxin A/B EIA is 97% specifi c, but since its sensitivity may be as low as 73%, it too should not be used alone. 6 Nucleic acid amplifi cation tests such as PCR and loop-mediated isothermal amplification (LAMP) identify toxigenic C diffi cile by detecting tcdA, tcdB, or tcdC genes, which regulate toxin production. These tests have sensitivities and specifi cities well over 90%. 6 Since molecular tests (ie, nucleic acid amplifi cation tests) for C diffi cile infection became available in 2009, they have been widely adopted and are commercially available. 7 Facilities that use them have reported a 50% to 100% increase in C diffi cile infection rates, 7 but the increase may not be real. Rather, it may refl ect increased detection of colonization by the more-sensitive tests.
In a prospective, observational, cohort study, 7 1,416 hospitalized patients with diarrhea that developed 72 hours after hospitalization were tested for C diffi cile infection by both toxin EIA and PCR. Those with positive results on both tests had a longer duration of diarrhea, more C diffi cile infection-related complications, more C diffi cile infection-related deaths, and greater risk of diarrhea during follow-up. For those who had negative results on toxin EIA testing, the results of PCR testing made no difference, and neither did treatment for C diffi cile infection, suggesting that most patients with negative toxin test results do not need treatment for C diffi cile even if PCR testing is positive.
In light of the limited sensitivity of some toxin EIAs and the increased identifi cation of asymptomatic colonization with nucleic acid amplifi cation testing, the optimal approach may be to combine rapid testing methods. Algorithms that include nucleic acid amplifi cation testing have the best sensitivity (68% to 100%) and specifi city (92% to 100%). 7 Clinical guidelines suggest using a GDH EIA as the initial step, and then confi rming positive results with either nucleic acid amplifi cation testing alone or toxin EIA followed by nucleic acid amplifi cation testing if the toxin EIA is negative. 8 However, the best diagnostic approach remains controversial, and multistep algorithms may be impractical in some laboratories.
Knowledge of the laboratory test used can help clinicians appreciate the limitations of speci- STOOL TESTING men testing. Table 1 outlines some of the performance characteristics of the available assays.
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The preferred approach at our institution is a multistep algorithm using both the GDH and toxin EIAs in the initial step, followed by a LAMP assay for the C diffi cile toxin genes in cases of discordant EIA results.
Repeat testing after an initial negative test may be positive in fewer than 5% of cases, can increase the chance of false-positive results, does not improve sensitivity and negative predictive values, and is therefore not recommended. 2, 8 Similarly, a test of cure after symptoms resolve is not recommended, as the toxin EIA can be positive for up to 30 days after resolution of symptoms, and a positive nucleic acid amplifi cation test may only refl ect colonization.
2,8 ■ RETURNING TO OUR PATIENT
Returning to the patient hospitalized with community-acquired pneumonia, C diffi cile infection is the most likely cause of her diarrhea. If her respiratory symptoms have improved, then cessation of ceftriaxone and azithromycin should be considered because she has completed 5 days of therapy. In addition, given her profuse diarrhea, testing for C diffi cile is recommended with a multistep approach. 
